|
1
|
Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle.
|
Cell Metab
|
2005
|
4.65
|
|
2
|
Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban.
|
Science
|
2003
|
3.71
|
|
3
|
Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy.
|
Circulation
|
2003
|
2.28
|
|
4
|
Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension.
|
Am J Physiol Heart Circ Physiol
|
2010
|
2.03
|
|
5
|
Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease.
|
J Mol Cell Cardiol
|
2007
|
1.42
|
|
6
|
IL-12 is required for differentiation of pathogenic CD8+ T cell effectors that cause myocarditis.
|
J Clin Invest
|
2003
|
1.31
|
|
7
|
Cardiac myosin missense mutations cause dilated cardiomyopathy in mouse models and depress molecular motor function.
|
Proc Natl Acad Sci U S A
|
2006
|
1.29
|
|
8
|
SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.
|
Cardiovasc Res
|
2009
|
1.12
|
|
9
|
High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4.
|
Mol Med
|
2013
|
1.02
|
|
10
|
Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations.
|
Circulation
|
2007
|
0.98
|
|
11
|
Functional role of AMP-activated protein kinase in the heart during exercise.
|
FEBS Lett
|
2005
|
0.97
|
|
12
|
A PRKAG2 mutation causes biphasic changes in myocardial AMPK activity and does not protect against ischemia.
|
Biochem Biophys Res Commun
|
2007
|
0.95
|
|
13
|
SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy.
|
J Mol Cell Cardiol
|
2010
|
0.95
|
|
14
|
E2F3 plays an essential role in cardiac development and function.
|
Cell Cycle
|
2008
|
0.94
|
|
15
|
Consequences of pressure overload on sarcomere protein mutation-induced hypertrophic cardiomyopathy.
|
Circulation
|
2003
|
0.92
|
|
16
|
Activation of cardiac hypertrophic signaling pathways in a transgenic mouse with the human PRKAG2 Thr400Asn mutation.
|
Biochim Biophys Acta
|
2009
|
0.92
|
|
17
|
Alterations of phospholamban function can exhibit cardiotoxic effects independent of excessive sarcoplasmic reticulum Ca2+-ATPase inhibition.
|
Circulation
|
2009
|
0.84
|
|
18
|
Functional effects of the TMEM43 Ser358Leu mutation in the pathogenesis of arrhythmogenic right ventricular cardiomyopathy.
|
BMC Med Genet
|
2012
|
0.84
|
|
19
|
Somatic mutations in pulmonary arterial hypertension: primary or secondary events?
|
Am J Respir Crit Care Med
|
2010
|
0.81
|
|
20
|
Early treatment with fumagillin, an inhibitor of methionine aminopeptidase-2, prevents Pulmonary Hypertension in monocrotaline-injured rats.
|
PLoS One
|
2012
|
0.80
|
|
21
|
Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy.
|
Eur J Heart Fail
|
2014
|
0.77
|
|
22
|
The genomic complexity underlying pulmonary arterial hypertension: from mendel to networks.
|
Am J Respir Crit Care Med
|
2014
|
0.76
|
|
23
|
Toward systems biology of pulmonary hypertension.
|
Circulation
|
2012
|
0.76
|
|
24
|
Autosomal recessive transmission of MYBPC3 mutation results in malignant phenotype of hypertrophic cardiomyopathy.
|
PLoS One
|
2013
|
0.76
|
|
25
|
Midterm outcomes of off-pump and on-pump coronary artery revascularization in renal transplant recipients.
|
J Card Surg
|
2011
|
0.75
|